Our laboratory has identified a number of small molecules that bind to Gbg subunits and selectively modify signaling responses downstream of GPCRs that signal at least in part through Gbg. I will discuss the initial discovery and validation of prototype compounds and application of compounds that inhibit Gbg signaling in animal models of therapeutics, with a focus on inflammatory disease. Finally I will discuss our progress on screening for novel chemical scaffolds for Gbg modulation that could become leads for pharmaceutical development for treatment of heart disease, inflammation and pain.
Alan Smrcka, Ph.D.
Professor of Pharmacology
Department of Pharmacology
University of Michigan Medical School
12:00 pm at Van Andel Institute
Conference Room 3104/3105
For questions, please contact Kim Cousineau at 616.234.5684.